Welcome to the e-CCO Library!

DOP30: Identifying dietary factors and metabolites that may promote healthier Crohn Disease microbiome and mucosal transcriptomics signals as future targets using Diet-Omics
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Haberman Ziv, Y.(1)*;Braun, T.(1);Amir, A.(1);Levhar, N.(1);Toren, I.(1);Malik, A.(2);Neuman, S.(2);Hadar, R.(1);Efroni, G.(1);Ben-Horin, S.(2);
Created: Friday, 14 July 2023, 10:43 AM
DOP30: Long-term outcomes of Crohn’s perianal fistulas treatment: anti-TNF with surgical closure versus anti-TNF alone (PISA-II) - A patient preference RCT
Year: 2022
Source: ECCO'22
Authors: Meima - van PraagMD, E.(1);Stoker, J.(2);D'Haens, G.(3);Gecse, K.(4);Dijkgraaf, M.(5);Bemelman, W.(1);Buskens, C.(1);
Created: Friday, 11 February 2022, 3:52 PM
DOP30: Multi-‘omics profiling in patients with quiescent Inflammatory Bowel Disease identifies biomarkers predicting relapse
Year: 2020
Source: ECCO'20 Vienna
Authors: Nynke Borren
Created: Tuesday, 23 June 2020, 4:58 PM
Files: 1
DOP30: Segmental vs extended colectomy for colorectal cancer in Crohn’s Disease: Results from a multi-centre retrospective comparative study
Year: 2021
Source: ECCO'21 Virtual
Authors: Sensi, B.(1);Khan, J.(2);Janindra, W.(3);siragusa, L.(1);panis, Y.(4);frontali, A.(4);Stefan, S.(5);Bellato, V.(6);Espin Basany, E.(7);Marti-Gallostra, M.(7);Frasson, M.(8);Garcia Granero, E.(9);spinelli, A.(10);carvello, M.(10);Sampietro, G.(11);fichera, A.(12);Artigue, M.(12);Zaghiyan, K.(13);Adams, E.(14);Konishi, T.(15);pellino, G.(16);Sica, G.(1)
Created: Wednesday, 2 June 2021, 4:12 PM
DOP31 Serum protein markers for early and differential IBD diagnosis validated by machine learning approaches
Year: 2020
Source:

ECCO'20 Vienna

Authors:

S. Verstockt1,2, N. Verplaetse2,3, D. Raimondi3, B. Verstockt1,4, E. Glorieus5, M. De Decker6, L. Hannes2, V. Ballet4, E. Vandeput1, Y. Moreau3, M. Ferrante1,4, D. Laukens5, F. Mana6, M. De Vos5, S. Vermeire1,4, I. Cleynen2

Created: Thursday, 30 January 2020, 10:12 AM
DOP31: Development and validation of the IBD-REFER criteria: when should a general practitioner or paediatrician refer a patient for suspected IBD?
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

O. Atia1, G. Focht1, A. Assa2, B. Yerushalmi3, R. Shaoul4, D. S. Shouval5, A. Bar-Gil Shitrit6, B. Koslowsky6, I. Dotan7, R. Kariv8, E. Lavon8, D. Turner*1

Created: Friday, 22 February 2019, 9:41 AM
DOP31: Development and validation of the IBD-REFER criteria: when should a general practitioner or pediatrician refer a patient for suspected IBD?
Year: 2019
Source: ECCO'19 Copenhagen
Authors: Dan Turner
Created: Tuesday, 28 May 2019, 3:32 PM
Files: 1
DOP31: Efficacy and safety of bone marrow-derived mesenchymal stem cells in refractory perianal fistulae in Crohn’s Disease: Results from a prospective monocentric study
Year: 2022
Source: ECCO'22
Authors: Reenaers Dr, C.(1);Vieujean , S.(1);Coimbra , C.(2);Gillard , R.(3);Meunier , P.(3);Boutaffala , L.(1);Louis , E.(1);
Created: Friday, 11 February 2022, 3:52 PM
DOP31: Gut metabolomic and compositional signatures predict response to treatment with exclusive enteral nutrition in children with active Crohn's disease
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Gerasimidis, K.(1)*;Nichols, B.(1);Briola, A.(1);Havlik, J.(2);Mascellani, A.(2);Milling, S.(3);Ijaz, U.(4);Quince, C.(5);Svolos, V.(1);Russell, R.K.(6);Hansen, R.(7);
Created: Friday, 14 July 2023, 10:43 AM
DOP31: Gut metabolomic and compositional signatures predict response to treatment with exclusive enteral nutrition in children with active Crohn’s disease
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Konstantinos Gerasimidis
Created: Friday, 14 July 2023, 2:22 PM
DOP31: Management and outcome of postoperative Crohn’s Disease in the elderly as compared to young adults: Data from Eneida registry
Year: 2021
Source: ECCO'21 Virtual
Authors: Mañosa Ciria, M.(1,2);Calafat, M.(1,2);Ricart, E.(2,3);Nos, P.(2,4);Iglesias, E.(5);Riestra, S.(6);López-Sanroman, A.(7);Vera, M.(8);Guardiola, J.(9);Hernández, V.(10);Rivero, M.(11);Carpio, D.(12);Mínguez, M.(13);Alba, C.(14);Martín-Arranz, M.D.(15);Rodríguez, E.(16);Gomollon, F.(17);Garcia-López, S.(18);Gutiérrez Casbas, A.(2,19,20);Calvet, X.(2,21);González-Muñoza, C.(22);Barrio, J.(23);P Gisbert, J.(2,24);Sicilia, B.(25);Pérez-Calle, J.L.(26);Bujanda, L.(2,27);Esteve, M.(2,28);Ramos, L.(29);Varela, P.(30);Sierra, M.(31);Merino, O.(32);Bermejo, F.(33,34);Barreiro-de Acosta, M.(35);Rodríguez, A.(36);Márquez, L.(37);Garcia-Bosch, O.(38);Cabriada, J.L.(39);Lorente, R.(40);Cañete, F.(1,2);Domènech, E.(1,2)
Created: Wednesday, 2 June 2021, 4:12 PM
DOP32 Clinical and molecular characterisation of patients with durable response to ustekinumab induction therapy: Results from the UNIFI phase 3 studies in moderate-to-severe ulcerative colitis
Year: 2020
Source:

ECCO'20 Vienna

Authors:

K. Li, F. Yang, K. Hayden, D. Strawn, E. Wadman, S. Bhagat, C. Marano, J.R. Friednman

Created: Thursday, 30 January 2020, 10:12 AM
DOP32: Biologic treatment does not reduce the risk of postoperative peristomal pyoderma gangrenosum in Crohn’s Disease patients
Year: 2022
Source: ECCO'22
Authors: Iesalnieks, I.(1);
Created: Friday, 11 February 2022, 3:52 PM
DOP32: Crohn's disease stricture matrisome analysis reveals the anti-fibrotic activity of milk-fat globule-epidermal growth factor 8 (MFGE8)
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Lin, S.(1);Wang, J.(2);Mukherjee, P.(3);Mao, R.(1);West, G.(3);Czarnecki, D.(3);Zhao, S.(3);Elias, M.(3);Nguyen, Q.T.(3);Chandra, J.(3);Le, T.H.N.(3);Chen, M.H.(1);Dejanovic, D.(3);Holubar, S.(4);Olman, M.(3);Southern, B.(3);Hu, S.(5);Gordon, I.O.(5);Atabai, K.(6);Fiocchi, C.(3);Rieder, F.(7)*;
Created: Friday, 14 July 2023, 10:43 AM
DOP32: Crohn’s disease stricture matrisome analysis reveals the anti-fibrotic activity of milk-fat globule-epidermal growth factor 8 (MFGE8)
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Florian Rieder
Created: Friday, 14 July 2023, 2:22 PM
DOP32: Long-term outcomes of enterocutaneous fistula complicating Crohn’s Disease: The ECUFIT study from GETECCU
Year: 2021
Source: ECCO'21 Virtual
Authors: Rodríguez-Lago, I.(1);García Pérez, C.(2);Calafat, M.(3);Soto, M.P.(4);Calvo, M.(5);Sánchez Rodríguez, E.(6);Caballol, B.(7);Vela, M.(8);Rivero, M.(9);Muñoz, F.(10);De Castro, L.(11);Calvet, X.(12);García-Alonso, F.J.(13);Utrilla Fornals, A.(14);Ferreiro-Iglesias, R.(15);González-Muñoza, C.(16);Chaparro, M.(17);Luis, B.(18);Sicilia, B.(19);Alfambra, E.(20);Rodriguez, A.(21);Pérez Fernández, R.(22);Rodríguez, C.(23);Almela, P.(24);Argüelles, F.(25);Busquets, D.(26);Tamarit-Sebastián, S.(27);Reygosa Castro, C.(28);Jiménez, L.(29);Marín-Jiménez, I.(30);Alcaide, N.(31);Fernández-Salgado, E.(32);Iglesias Gómez, Á.(33);Ponferrada, Á.(34);Pajares, R.(35);Roncero, Ó.(36);Morales-Alvarado, V.J.(37);Cabriada, J.L.(1);Domènech, E.(3);Barreiro-de Acosta, M.(15)
Created: Wednesday, 2 June 2021, 4:12 PM
DOP32: Withdrawal of thiopurines in Crohn’s disease treated with scheduled adalimumab maintenance: a prospective randomised clinical trial (DIAMOND2)
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

T. Hisamatsu*1, S. Kato2, R. Kunisaki3, M. Matsuura4, M. Nagahori5, S. Motoya6, M. Esaki7, N. Fukata8, S. Inoue9, T. Sugaya10, H. Sakuraba11, F. Hirai12, K. Watanabe13,14, T. Kanai15, M. Naganuma15, H. Nakase16, Y. Suzuki17, M. Watanabe5, T. Hibi18, M. Nojima19, T. Matsumoto20, DIAMOND2 Study Group1

Created: Friday, 22 February 2019, 9:41 AM
DOP32: Withdrawal of thiopurines in Crohn’s disease treated with scheduled adalimumab maintenance: a prospective randomised clinical trial (DIAMOND2)
Year: 2019
Source: ECCO'19 Copenhagen
Authors: Tadakazu Hisamatsu
Created: Tuesday, 28 May 2019, 3:32 PM
Adalimumab, Anti-TNF agents, Thiopurines (AZA / MP), Disease activity indices, Mucosal healing
Files: 1